Lupus anticoagulant: a potential risk factor for complication following percutaneous transluminal coronary angioplasty

P Anglin; B H Strauss; J M Brandwein; K R Watson

doi:10.1002/ccd.1810310208

Lupus anticoagulant: a potential risk factor for complication following percutaneous transluminal coronary angioplasty

Cathet Cardiovasc Diagn. 1994 Feb;31(2):130-2. doi: 10.1002/ccd.1810310208.

Authors

P Anglin¹, B H Strauss, J M Brandwein, K R Watson

Affiliation

¹ Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.

PMID: 8149425
DOI: 10.1002/ccd.1810310208

Abstract

A patient is described with antiphospholipid antibodies who died approximately 24 hr after an uncomplicated balloon angioplasty. Since the literature suggests a relationship between the presence of antiphospholipid antibodies and thromboses, we suggest that these antibodies may be a risk factor for abrupt closure after percutaneous transluminal coronary angioplasty.

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Review

MeSH terms

Adult
Angioplasty, Balloon, Coronary*
Antiphospholipid Syndrome / blood
Antiphospholipid Syndrome / complications
Antiphospholipid Syndrome / mortality
Coronary Angiography
Fatal Outcome
Humans
Lupus Coagulation Inhibitor / blood*
Male
Myocardial Infarction / blood
Myocardial Infarction / mortality
Myocardial Infarction / therapy*
Risk Factors

Substances

Lupus Coagulation Inhibitor